MX2020000752A - Combinaciones farmaceuticas que comprenden un anticuerpo anti bst-1 y un analogo de citidina. - Google Patents
Combinaciones farmaceuticas que comprenden un anticuerpo anti bst-1 y un analogo de citidina.Info
- Publication number
- MX2020000752A MX2020000752A MX2020000752A MX2020000752A MX2020000752A MX 2020000752 A MX2020000752 A MX 2020000752A MX 2020000752 A MX2020000752 A MX 2020000752A MX 2020000752 A MX2020000752 A MX 2020000752A MX 2020000752 A MX2020000752 A MX 2020000752A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical combinations
- bst
- antibody
- cytidine analogue
- bst1
- Prior art date
Links
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 title abstract 2
- 101100326371 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) bst-1 gene Proteins 0.000 title 1
- 102100029824 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Human genes 0.000 abstract 5
- 101000794082 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Proteins 0.000 abstract 3
- 101001099051 Homo sapiens GPI inositol-deacylase Proteins 0.000 abstract 3
- 108010046643 ADP-ribosyl cyclase 2 Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1711785.4A GB201711785D0 (en) | 2017-07-21 | 2017-07-21 | Antibodies |
| PCT/EP2018/069768 WO2019016371A1 (en) | 2017-07-21 | 2018-07-20 | PHARMACEUTICAL ASSOCIATIONS COMPRISING ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOG |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000752A true MX2020000752A (es) | 2020-08-17 |
Family
ID=59771583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000752A MX2020000752A (es) | 2017-07-21 | 2018-07-20 | Combinaciones farmaceuticas que comprenden un anticuerpo anti bst-1 y un analogo de citidina. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20200231694A1 (enExample) |
| EP (1) | EP3655033A1 (enExample) |
| JP (1) | JP2020527594A (enExample) |
| KR (1) | KR20200032162A (enExample) |
| CN (1) | CN111132697A (enExample) |
| AR (1) | AR112460A1 (enExample) |
| AU (1) | AU2018303241A1 (enExample) |
| BR (1) | BR112020001320A2 (enExample) |
| CA (1) | CA3070264A1 (enExample) |
| CL (1) | CL2020000175A1 (enExample) |
| CO (1) | CO2020001792A2 (enExample) |
| EA (1) | EA202090333A1 (enExample) |
| GB (1) | GB201711785D0 (enExample) |
| IL (1) | IL272096A (enExample) |
| MA (1) | MA49627A (enExample) |
| MX (1) | MX2020000752A (enExample) |
| PH (1) | PH12020550024A1 (enExample) |
| SG (1) | SG11202000390TA (enExample) |
| TW (1) | TW201907952A (enExample) |
| UY (1) | UY37815A (enExample) |
| WO (1) | WO2019016371A1 (enExample) |
| ZA (1) | ZA202000881B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004063494A1 (de) * | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
| WO2013003625A2 (en) * | 2011-06-28 | 2013-01-03 | Oxford Biotherapeutics Ltd. | Antibodies |
| GB201806084D0 (en) * | 2018-04-13 | 2018-05-30 | Berlin Chemie Ag | Antibodies |
| CN118178645A (zh) * | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
-
2017
- 2017-07-21 GB GBGB1711785.4A patent/GB201711785D0/en not_active Ceased
-
2018
- 2018-07-20 WO PCT/EP2018/069768 patent/WO2019016371A1/en not_active Ceased
- 2018-07-20 CN CN201880060959.0A patent/CN111132697A/zh active Pending
- 2018-07-20 US US16/632,195 patent/US20200231694A1/en not_active Abandoned
- 2018-07-20 AR ARP180102042 patent/AR112460A1/es not_active Application Discontinuation
- 2018-07-20 AU AU2018303241A patent/AU2018303241A1/en not_active Abandoned
- 2018-07-20 JP JP2020503018A patent/JP2020527594A/ja not_active Withdrawn
- 2018-07-20 SG SG11202000390TA patent/SG11202000390TA/en unknown
- 2018-07-20 TW TW107125058A patent/TW201907952A/zh unknown
- 2018-07-20 EP EP18746656.0A patent/EP3655033A1/en not_active Withdrawn
- 2018-07-20 BR BR112020001320-0A patent/BR112020001320A2/pt not_active IP Right Cessation
- 2018-07-20 CA CA3070264A patent/CA3070264A1/en active Pending
- 2018-07-20 EA EA202090333A patent/EA202090333A1/ru unknown
- 2018-07-20 MA MA049627A patent/MA49627A/fr unknown
- 2018-07-20 MX MX2020000752A patent/MX2020000752A/es unknown
- 2018-07-20 KR KR1020207005030A patent/KR20200032162A/ko not_active Withdrawn
- 2018-07-20 UY UY0001037815A patent/UY37815A/es not_active Application Discontinuation
-
2020
- 2020-01-16 IL IL272096A patent/IL272096A/en unknown
- 2020-01-16 PH PH12020550024A patent/PH12020550024A1/en unknown
- 2020-01-20 CL CL2020000175A patent/CL2020000175A1/es unknown
- 2020-02-11 ZA ZA2020/00881A patent/ZA202000881B/en unknown
- 2020-02-18 CO CONC2020/0001792A patent/CO2020001792A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2020001792A2 (es) | 2020-07-31 |
| BR112020001320A2 (pt) | 2020-08-11 |
| WO2019016371A1 (en) | 2019-01-24 |
| JP2020527594A (ja) | 2020-09-10 |
| GB201711785D0 (en) | 2017-09-06 |
| PH12020550024A1 (en) | 2021-02-15 |
| CN111132697A (zh) | 2020-05-08 |
| CA3070264A1 (en) | 2019-01-24 |
| UY37815A (es) | 2019-02-28 |
| EP3655033A1 (en) | 2020-05-27 |
| CL2020000175A1 (es) | 2020-06-12 |
| TW201907952A (zh) | 2019-03-01 |
| KR20200032162A (ko) | 2020-03-25 |
| AR112460A1 (es) | 2019-10-30 |
| SG11202000390TA (en) | 2020-02-27 |
| US20200231694A1 (en) | 2020-07-23 |
| ZA202000881B (en) | 2021-08-25 |
| IL272096A (en) | 2020-03-31 |
| AU2018303241A1 (en) | 2020-02-20 |
| EA202090333A1 (ru) | 2020-05-06 |
| MA49627A (fr) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| TN2018000005A1 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MY202018A (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| MY169165A (en) | Anti-pdgfr-beta antibodies and uses thereof | |
| PH12019502576A1 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| JOP20200231A1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| MX2019012285A (es) | Metodos de tratamiento de encefalopatias del desarrollo. | |
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| MX383975B (es) | Derivado de anillo fusionado como inhibidor del receptor a2a | |
| MX2019008773A (es) | Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos. | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
| BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
| PH12020550024A1 (en) | Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue | |
| MX379140B (es) | Sal de etano-sulfonato del derivado de quinolina. | |
| MX2022000317A (es) | Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5. | |
| JOP20220074A1 (ar) | أجسام مضادة لـ nrp1a واستخداماتها لعلاج العين أو أمراض العين | |
| NZ749172A (en) | 4,6-diaminoquinazolines as cot modulators and methods of use thereof | |
| EA201990712A1 (ru) | Лечение рассеянного склероза посредством chs-131 | |
| JO3621B1 (ar) | مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll |